Thermo Fisher Scientific Stock News

As the pandemic winds down, the market anticipates losing the tailwind from Covid activities, and has punished the entire life science sector. Thermo Fisher was part of this sell-off.

Thermo Fisher Scientific (TMO) has filed for a mixed shelf offering of a yet to be determined amount.

Thermo Fisher's (TMO) strong pandemic response stance enables it to accelerate its growth strategy, and bump up investments, which encourages it to raise the 2022 core organic growth guidance.

This article was originally published on TipRanks.com Scientific instrumentation and software services provider Thermo Fisher Scientific Inc. The post Thermo Fisher Rewards Shareholders with 15.4% Dividend Hike appeared first on Smarter Analyst .

Thermo Fisher Scientific (TMO) declares $0.30/share quarterly dividend, 15% increase from prior dividend of $0.26.

Moderna and Thermo Fisher Enter Long-Term Collaboration

Moderna Inc (NASDAQ: MRNA ) has entered into a long-term agreement with Thermo Fisher Scientific Inc (NYSE: TMO ) to manufacture its COVID-19 vaccine and other experimental medicines based on mRNA technology. Thermo Fisher had already partnered with Moderna last year to help scale up production of its COVID vaccine, … Full story available on Benzinga.com

It's been a tough year so far for Thermo Fisher Scientific Inc (NYSE: TMO), with the stock down nearly 20%, but Jim Lebenthal recommends patience because TMO will get its “mojo” back. Lebenthal ba

Moderna Inc has entered into a long-term agreement with Thermo Fisher Scientific for the manufacturing of its COVID-19 vaccine and other experimental medicines based on mRNA technology, the companies said on Wednesday.

Moderna (MRNA) and Thermo Fisher Scientific (TMO) have inked a 15-year strategic collaboration agreement. Read more on its details.

Moderna Inc. and life-sciences company Thermo Fisher Scientific Inc. said Wednesday they have entered a long-term agreement to collaborate on large-scale manufacturing of the former''s COVID-19 vaccine dubbed Spikevax and other therapies based on its mRNA technology. In a joint statement, the companies said they have already been working together to support Moderna''s pipeline with Thermo Fisher providing clinical research and contract manufacturing services, including aseptic fill-finish services and packaging of the COVID vaccine. The expanded agreement will see them offer capacity for other fill-finish services and provide inspection, labeling and final packaging services. Moderna shares were up 1.6% premarket, while Thermo Fisher shares were not yet active. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Moderna Inc. MRNA, -0.53% and life-sciences company Thermo Fisher Scientific Inc. TMO, -1.35% said Wednesday they have entered a long-term agreement to collaborate on large-scale manufacturing of the